Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marroon Thabane

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
World Journal of Gastroenterology|August 5, 2009
Post-infectious irritable bowel syndromeMarroon Thabane, John K Marshall
Digestive Diseases and Sciences|April 28, 2006
Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronateJohn K Marshall, Marroon Thabane, Cindy James
Current Oncology (Toronto, Ont.)|January 20, 2021
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast CancerDaniel Stellato, Marroon Thabane, Caitlin Eichten, et al.
JAMA|December 21, 2006
Acetaminophen and aminotransferase elevationsYuhong Yuan, Marroon Thabane, Lehana Thabane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 10, 2007
Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogenJohn K Marshall, Marroon Thabane, Mark R Borgaonkar, et al.
The American Journal of Gastroenterology|July 2, 2009
Development and validation of a risk score for post-infectious irritable bowel syndromeMarroon Thabane, Marko Simunovic, Noori Akhtar-Danesh, et al.
The American Journal of Gastroenterology|July 26, 2006
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysisSara Padol, Yuhong Yuan, Marroon Thabane, et al.
Breast Cancer (Dove Medical Press)|May 17, 2018
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancerAnna Forsythe, David Chandiwana, Janina Barth, et al.
Pharmacoeconomics|December 10, 2014
Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in CanadaThomas E Delea, Jordan Amdahl, Alice Wang, et al.
Cancer Management and Research|May 17, 2018
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Anna Forsythe, David Chandiwana, Janina Barth, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
World Journal of Gastroenterology|August 5, 2009
Post-infectious irritable bowel syndromeMarroon Thabane, John K Marshall
Digestive Diseases and Sciences|April 28, 2006
Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronateJohn K Marshall, Marroon Thabane, Cindy James
Current Oncology (Toronto, Ont.)|January 20, 2021
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast CancerDaniel Stellato, Marroon Thabane, Caitlin Eichten, et al.
JAMA|December 21, 2006
Acetaminophen and aminotransferase elevationsYuhong Yuan, Marroon Thabane, Lehana Thabane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 10, 2007
Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogenJohn K Marshall, Marroon Thabane, Mark R Borgaonkar, et al.
The American Journal of Gastroenterology|July 2, 2009
Development and validation of a risk score for post-infectious irritable bowel syndromeMarroon Thabane, Marko Simunovic, Noori Akhtar-Danesh, et al.
The American Journal of Gastroenterology|July 26, 2006
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysisSara Padol, Yuhong Yuan, Marroon Thabane, et al.
Breast Cancer (Dove Medical Press)|May 17, 2018
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancerAnna Forsythe, David Chandiwana, Janina Barth, et al.
Pharmacoeconomics|December 10, 2014
Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in CanadaThomas E Delea, Jordan Amdahl, Alice Wang, et al.
Cancer Management and Research|May 17, 2018
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Anna Forsythe, David Chandiwana, Janina Barth, et al.
Pageof 3